Skip to content
Screener

Net Income at other companies

Amgen logo
AmgenAMGN
$2.38B+65.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.3B-6.8%
Gilead Sciences logo
Gilead SciencesGILD
-$10.5B-636%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$127.12M-26.2%
Biohaven logo
BiohavenBHVN
-$130.53M+41.1%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$9.08M-3.0%

Segments

By segment

See full
Reportable Segment$80.08M+172%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.48B+111%
Enterprise value$1.29B+159%
P/S4.9×-32.1×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income6,7927,62913,55726,227
Income (loss) before provision for income taxes80,259(110,788)(45,266)(231,737)
Provision for income taxes(179)(170)(349)(186)
Net income (loss)$80,080$(110,958)$(45,615)$(231,923)
Net income (loss) per share, basic$0.48$(0.80)$(0.29)$(1.68)
Net income (loss) per share, diluted$0.47$(0.80)$(0.29)$(1.68)
Weighted-average shares outstanding, basic167,719,015138,447,469157,613,578137,960,888
Weighted-average shares outstanding, diluted168,879,127138,447,469157,613,578137,960,888

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s net income?
Vir Biotechnology, Inc. (VIR) reported net income of $80.08M in Q2 2026.
How has Vir Biotechnology, Inc.'s net income changed year-over-year?
Vir Biotechnology, Inc.'s net income increased by 172.2% year-over-year, from -$110.96M to $80.08M.
What is the long-term trend for Vir Biotechnology, Inc.'s net income?
Over 3 years (2021 to 2025), Vir Biotechnology, Inc.'s net income has grown at a -6.1% compound annual growth rate (CAGR), from $528.58M to -$437.99M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Vir Biotechnology, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude